Posted: Tuesday, June 11, 2024
Heather Wakelee, MD, of Stanford University Medical Center, discusses practical clinical questions regarding the latest phase III findings showing that atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC).